close

Fenwick Represents Agilent in $105 Million Acquisition of Lasergen

May 07, 2018

​​Fenwick & West represented Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, in its acquisition of the remaining shares of Lasergen, Inc., an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing, for $105 million.

The acquisition follows Agilent’s initial investment in Lasergen to acquire a 48-percent ownership stake with a two-year call option in March 2016. Agilent and Lasergen will continually work together to grow in the diagnostics space and build a complete routine clinical NGS workflow. More information about Agilent’s acquisition of Lasergen can be obtained from the company announcement.

The Fenwick transaction team included corporate lawyers Michael Brown, Maureen Montgomery and Tracy Kennberg; executive compensation and employee benefits lawyers Blake Martell and Liz Gartland; and tax lawyers Andrew Kim and David de Ruig.​​​